BR9610390A - O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i - Google Patents

O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i

Info

Publication number
BR9610390A
BR9610390A BR9610390A BR9610390A BR9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A BR 9610390 A BR9610390 A BR 9610390A
Authority
BR
Brazil
Prior art keywords
pct
thienotriazolodiazepine
apoliprotein
increase levels
sec
Prior art date
Application number
BR9610390A
Other languages
English (en)
Portuguese (pt)
Inventor
Herman Kempen
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR9610390A publication Critical patent/BR9610390A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
BR9610390A 1995-09-09 1996-08-30 O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i BR9610390A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP95114163 1995-09-09
PCT/EP1996/003814 WO1997009048A1 (en) 1995-09-09 1996-08-30 Use of a thienotriazolodiazepine to increase apolipoprotein a-i levels

Publications (1)

Publication Number Publication Date
BR9610390A true BR9610390A (pt) 1999-07-06

Family

ID=8219597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9610390A BR9610390A (pt) 1995-09-09 1996-08-30 O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i

Country Status (14)

Country Link
US (1) US5854238A (https=)
EP (1) EP0853480B1 (https=)
JP (1) JPH11512107A (https=)
KR (1) KR19990044460A (https=)
CN (1) CN1101680C (https=)
AT (1) ATE230600T1 (https=)
AU (1) AU725249B2 (https=)
BR (1) BR9610390A (https=)
CA (1) CA2230477A1 (https=)
DE (1) DE69625696T2 (https=)
DK (1) DK0853480T3 (https=)
ES (1) ES2188783T3 (https=)
TR (1) TR199800406T1 (https=)
WO (1) WO1997009048A1 (https=)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6518412B1 (en) * 1997-09-29 2003-02-11 Jean-Louis Dasseux Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6253569B1 (en) * 1999-05-07 2001-07-03 James J. Hall Portable storage unit for game animals
US7723303B2 (en) 2000-08-24 2010-05-25 The Regents Of The University Of California Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response
US7199102B2 (en) 2000-08-24 2007-04-03 The Regents Of The University Of California Orally administered peptides synergize statin activity
US6664230B1 (en) 2000-08-24 2003-12-16 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7166578B2 (en) 2000-08-24 2007-01-23 The Regents Of The University Of California Orally administered peptides synergize statin activity
US7144862B2 (en) 2000-08-24 2006-12-05 The Regents Of The University Of California Orally administered peptides to ameliorate atherosclerosis
US7148197B2 (en) * 2000-08-24 2006-12-12 The Regents Of The University Of California Orally administered small peptides synergize statin activity
US7429593B2 (en) 2001-09-14 2008-09-30 Shionogi & Co., Ltd. Utilities of amide compounds
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
EP2168576A3 (en) 2001-09-14 2010-05-26 Shionogi & Co., Ltd. Tricyclic compounds for treating dyslipidemia and arteriosclerotic diseases
US6930085B2 (en) * 2002-04-05 2005-08-16 The Regents Of The University Of California G-type peptides to ameliorate atherosclerosis
KR20070089996A (ko) 2004-12-06 2007-09-04 더 리전트 오브 더 유니버시티 오브 캘리포니아 세동맥의 구조 및 기능의 개선 방법
EP2195331B1 (en) 2007-08-28 2013-11-20 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
WO2009032702A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
ES2448567T3 (es) * 2008-10-30 2014-03-14 Circomed Llc Derivados de la tienotriazoldiazepina activos en apo A
PL2902030T3 (pl) 2010-05-14 2017-07-31 Dana-Farber Cancer Institute, Inc. Związki tienotriazolodiazepinowe do leczenia nowotworu
CN103119160B (zh) * 2010-05-14 2016-06-01 达那-法伯癌症研究所 用于调节代谢的组合物和方法
MX354217B (es) 2010-05-14 2018-02-19 Dana Farber Cancer Inst Inc Composiciones y metodos para el tratamiento de leucemia.
EP2571875A4 (en) 2010-05-14 2013-10-30 Dana Farber Cancer Inst Inc CONTRACEPTIVE COMPOSITIONS FOR MEN AND METHODS OF USE THEREOF
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
RU2016122654A (ru) 2013-11-08 2017-12-14 Дана-Фарбер Кэнсер Инститьют, Инк. Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка
EP3099677A4 (en) 2014-01-31 2017-07-26 Dana-Farber Cancer Institute, Inc. Diaminopyrimidine benzenesulfone derivatives and uses thereof
US10793571B2 (en) 2014-01-31 2020-10-06 Dana-Farber Cancer Institute, Inc. Uses of diazepane derivatives
JP2017506666A (ja) 2014-02-28 2017-03-09 テンシャ セラピューティクス，インコーポレイテッド 高インスリン血症に関連した症状の処置
WO2016018665A1 (en) 2014-07-31 2016-02-04 Uab Research Foundation Apoe mimetic peptides and higher potency to clear plasma cholesterol
CN106793775B (zh) 2014-08-08 2020-06-02 达纳-法伯癌症研究所股份有限公司 二氢碟啶酮衍生物及其用途
CN106715437A (zh) 2014-08-08 2017-05-24 达纳-法伯癌症研究所股份有限公司 二氮杂环庚烷衍生物及其用途
KR20170068597A (ko) 2014-10-27 2017-06-19 텐샤 세러퓨틱스 인코포레이티드 브로모도메인 저해제
WO2016201370A1 (en) 2015-06-12 2016-12-15 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
RU2018112953A (ru) 2015-09-11 2019-10-14 Дана-Фарбер Кэнсер Инститьют, Инк. Ацетамидтиенотриазолодиазепины и пути их применения
EP3347021A4 (en) 2015-09-11 2019-07-24 Dana-Farber Cancer Institute, Inc. CYANOTHIENOTRIAZOLDIAZEPINE AND USES THEREOF
MX2018006499A (es) 2015-11-25 2018-08-01 Dana Farber Cancer Inst Inc Inhibidores de bromodominio bivalentes y usos de los mismos.
AU2019284971A1 (en) 2018-06-13 2020-12-03 Worg Pharmaceuticals (Zhejiang) Co., Ltd. Preparation of condensed triazepine derivatives and their use as BET inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4155913A (en) * 1973-02-08 1979-05-22 Hoffmann-La Roche Inc. Thienotriazolodiazepine derivatives
PH12303A (en) * 1973-02-08 1979-01-16 Hoffmann La Roche Thienotriazolodiazepine derivatives
JPS50100096A (https=) * 1974-01-08 1975-08-08

Also Published As

Publication number Publication date
JPH11512107A (ja) 1999-10-19
DE69625696D1 (de) 2003-02-13
DE69625696T2 (de) 2003-10-16
DK0853480T3 (da) 2003-05-05
CN1101680C (zh) 2003-02-19
MX9801753A (es) 1998-08-30
CA2230477A1 (en) 1997-03-13
EP0853480B1 (en) 2003-01-08
AU725249B2 (en) 2000-10-12
AU6930396A (en) 1997-03-27
CN1195989A (zh) 1998-10-14
WO1997009048A1 (en) 1997-03-13
EP0853480A1 (en) 1998-07-22
US5854238A (en) 1998-12-29
ES2188783T3 (es) 2003-07-01
TR199800406T1 (en) 1998-05-21
KR19990044460A (ko) 1999-06-25
ATE230600T1 (de) 2003-01-15

Similar Documents

Publication Publication Date Title
BR9610390A (pt) O uso de uma tienotriazolodiazepina para aumentar os níveis da apoliproteína a-i
TR200101969T2 (tr) Enflamasyon tedavisi için sübstitüe edilmiş benzopiran analogları.
DK0801564T3 (da) Anvendelse af nebivolol som et antiatherogent middel
NO981944D0 (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
EE9800080A (et) (Metüülsulfonüül)fenüül-2-(5H)-furanoonid, nende kasutamine ja farmatseutilised kompositsioonid
BR9916565A (pt) Combinações de inibidores do transporte ácido da bile ileal e derivados do ácido fìbrico para indicações cardiovasculares
BR9813508A (pt) Inibição de replicação viral associada com membrana
ES2182914T3 (es) Inmunopotenciacion inducida de quitosan.
NO980296L (no) Forbedrede terapeutiske midler
AU4080097A (en) Piperazino derivatives as neurokinin antagonists
DE69629023D1 (de) Piperazino-derivative als neurokininantagonisten
ES2120667T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para tratamiento de dermatosis.
DK0722325T3 (da) Præparat til behandling eller forebyggelse af herpes
ATE169922T1 (de) Desoxyazaphospholipid-derivate mit inhibierender aktivität auf phospholipase
SE9301831D0 (sv) Pharmaceutical compositions
AR005866A1 (es) Composicion farmaceutica antioxidante
ES2093656T3 (es) Preparaciones combinadas farmaceuticas que contienen cefotaxima y derivados de la xantina y su uso.
ATE223427T1 (de) Modifizierte kojibioside analoge
BR9813098A (pt) Uso de glicosaminoglicans, preparação farmacêutica, e, combinaçào
KR960700053A (ko) 방사선회복제로서 리루졸의 이용(application of riluzole as a radiorestorer)
AR009470A1 (es) COMPOSICIoN FARMACÉUTICA QUE CONTIENE CEPAS BACTERIANAS Y UTILES EN EL TRATAMIENTO DE ENFERMEDADES ASOCIADAS CON O CAUSADAS POR ALTERACIONES EN EL METABOLISMO DE LOS ÁCIDOS BILIARES, Y USO DE LAS MISMAS.
DE69428127D1 (de) Schädlingsbekämpfungsmittel
BR9704686A (pt) Grupos de bactérias e composição farmacêutica contendo tais grupos, e uso da mesma para impedir e tratar doenças associadas com, ou causadas pelo metabolismo alterado de ácido de bìlis.

Legal Events

Date Code Title Description
HHB Publication of an application: rectification
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
EG Technical examination (opinion): publication of technical examination (opinion)
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFERIMENTO DO PRENTE PEDIDO, COM BASE NOS ARTIGOS 8 E 11 DA LPI E DADO COM CONCLUIDO O EXAME.